Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Hits Pause On Business Development, Even As Some Deals Stumble

Executive Summary

Teva CEO Erez Vigodman said the company will step away from business development for the “foreseeable future” while it digests the acquisition of Allergan’s generic drug business.

Advertisement

Related Content

Teva Undertaking Strategic Review As It Searches For New CEO
Teva CEO Steps Down While An Integration Hangs In The Balance
Teva Appoints New Global Generics Head Amid Massive Integration
Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Stockwatch: The Post-Truth Biopharma Rally
Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
Teva Adds Needed Latin American Puzzle Piece With Rimsa Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097679

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel